MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Gilead Sciences DPO Ratio 2011-2026 | GILD
Annual DPO Ratio Gilead Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45.3 | 40.4 | 40.9 | 51.9 | 42.8 | 62.2 | 55.7 | 59.4 | 68 | 103 | 107 | 92 | 160 | 196 | 207 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 207 | 40.4 | 88.9 |
Quarterly DPO Ratio Gilead Sciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 40.4 | 40.1 | 46.5 | - | 41.7 | 34.2 | 34.5 | - | 35.2 | 39.5 | 49.9 | - | 38.6 | 36.3 | 41.3 | - | 44.5 | 38.7 | 47.4 | - | 67.5 | 72.4 | 73.3 | - | 62.9 | 65.1 | 71.7 | - | 66.4 | 60.3 | 73.1 | - | 72 | 66 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 73.3 | 34.2 | 52.3 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
4.39 K | - | 4.01 % | $ 150 M |  Canada |
 |
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | USA |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M |  China |
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aptorum Group Limited
APM
|
405 | $ 0.82 | 4.22 % | $ 4.47 M | China |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
BioCardia
BCDA
|
68.1 K | $ 1.37 | 7.87 % | $ 29 M | USA |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M | Canada |
 |
Catalyst Biosciences
CBIO
|
7.82 | $ 11.29 | -2.5 % | $ 1.01 B | USA |
 |
Anika Therapeutics
ANIK
|
54.4 | $ 14.61 | 1.71 % | $ 214 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
235 | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |  Israel |
 |
Aytu BioScience
AYTU
|
186 | $ 2.64 | - | $ 16.6 M | USA |
 |
CorMedix
CRMD
|
79.3 | $ 6.57 | 0.46 % | $ 473 K | USA |